Journal
NATURE IMMUNOLOGY
Volume 16, Issue 8, Pages 850-+Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ni.3201
Keywords
-
Categories
Funding
- Institut Pasteur (Pasteur-Roux post-doctoral fellowship)
- Pasteur Foundation
- Ligue Contre le Cancer
- Fondation ARC pour la recherche sur le cancer
- French government's Invest in the Future Program
Ask authors/readers for more resources
The success of antitumor immune responses depends on the infiltration of solid tumors by effector T cells, a process guided by chemokines. Here we show that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10 and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide direct in vivo evidence for control of lymphocyte trafficking via CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing biologically active forms of chemokines as a strategy to enhance tumor immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available